Our goal is that by 2030, all patients in countries where we operate who need our medicines will have access to them.
Aligned with how sustainability is our business approach, and our commitment to UN SDG #3 (to ensure healthy lives and promote wellbeing for all at all ages) we work in the countries where we operate to enable access to our solutions for all patients who need them, in a way which is viable for patients, society, and UCB. In addition, we focus on improving access to quality care and medicines for people with epilepsy in low- and medium-income countries . We recognize there are many challenges which may prevent access to medicines, including the time taken for new medicines to be made available in a market, reimbursement practices, and affordability.
We focus on the unmet needs of patients and identifying the right patients early who could benefit from our medicines.
We aspire to improve equitable access for patients by securing access to our solutions in a timely fashion, measuring progress on access and affordability, and better demonstrating the value of medicines to patients, healthcare systems, and society. UCB wants to be part of the solution towards equitable access, developing and implementing innovative, differentiated solutions that provide demonstrable value to patients – improving their lives now and into the future.
With this in mind, we have defined access as the ability of a patient to obtain in a timely fashion, the medicine they need.
Please note that access-related risks are reported in the Risk Management section of this report.
- 1 For the 2021 fiscal year, and in line with World Bank. Atlas calculation methods, low-income economies are defined as those with a GNI per capita of $1,035 or less in 2019; lower middle-income economies are those with a GNI per capita between $1,036 and $4,045; upper middle-income economies are those with a GNI per capita between $4,046 and $12,535; high-income economies are those with a GNI per capita of $12,536 or more.